98%
921
2 minutes
20
Background: Despite being integral to the deprescribing process, integration of shared decision making (SDM) into structured deprescribing interventions and its relation to patient outcomes remain understudied.
Methods: We conducted a scoping review of PubMed/MEDLINE, Embase, Scopus, and PsycInfo (through September 2023) with a medical librarian's guidance. Studies of SDM interventions for deprescribing in older adults with polypharmacy were included. Two independent reviewers performed screening and data abstraction. An iterative narrative synthesis was conducted to categorize the core functions (purposes) and forms (specific activities) of the identified interventions, along with their measured outcomes, including SDM-related outcomes.
Results: Among 5402 retrieved records, 14 studies of 12 distinct interventions met the inclusion criteria. Studies were published between 2017 and 2023 and described a pilot implementation (n = 3), randomized controlled trials (n = 9), or patient interviews assessing perceptions regarding interventions (n = 2). Most interventions (n = 9) evaluated were specific to the outpatient setting and led by primary care physicians (n = 6) or pharmacists (n = 3). Two (n = 2) were hospital-based, involving pharmacists with nurse practitioners or physicians, and one (n = 1) took place in nursing homes, led by nurses. Along with patient and medication identification (n = 12) and SDM (n = 12), common core functions included decision support (n = 7), care coordination (n = 5), coordinating follow-up and monitoring (n = 3), and family/caregiver involvement (n = 2). Only 4 studies explicitly mentioned an SDM framework, the Three-Talk Model (n = 2), AHRQ SHARE (n = 1), and the Collaborative Deliberation Model (n = 1); only three (n = 3) explicitly measured whether SDM occurred. The majority reported positive associations between the SDM interventions and medication use (n = 6) and deprescribing behaviors (n = 8).
Conclusions: There is substantial variability in how deprescribing interventions incorporate SDM. Most studies do not empirically measure SDM. While SDM is associated with improved satisfaction and process of care outcomes, evidence regarding the impact of SDM-informed deprescribing interventions and patient behavioral and health outcomes is inconclusive.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jgs.70059 | DOI Listing |
Acta Anaesthesiol Scand
October 2025
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Background: This study assessed the prevalence and incidence of potentially inappropriate medication use for older patients undergoing surgery and its association with polypharmacy.
Methods: A retrospective, population-based cohort study with patients ≥ 65 undergoing first surgery at Landspitali-The National University Hospital of Iceland from 2005 to 2018. Participants were categorized by number of medications filled before and following their surgical episode into: non-polypharmacy (< 5), polypharmacy (5-9), and hyper-polypharmacy (≥ 10).
Fam Pract
August 2025
Department of General Practice, Amsterdam University Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Background: Elderly patients with Type 2 diabetes (T2D) are frequently overtreated with glucose-lowering medication.
Objective: This feasibility study evaluated the implementation of a deprescribing programme (DPP) for general practices, consisting of education, a patient selection tool, practice visits, and an expert support panel, before scaling it in a randomized controlled trial.
Methods: Quantitative evaluation included the number of patients with T2D eligible for deprescribing using medical records and study progress data.
Basic Clin Pharmacol Toxicol
October 2025
Clinical Pharmacy and Pharmacoepidemiology Research Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium.
Although physicians are primarily responsible for Benzodiazepine Receptor Agonist (BZRA) deprescribing, nonphysician healthcare professionals (HCPs) can support deprescribing. This study explored barriers to and enablers of BZRA deprescribing among nonphysician HCPs. We surveyed 258 HCPs (63.
View Article and Find Full Text PDFDrugs Aging
September 2025
Clinical Center of Excellence for Older Adults with Personality Disorders, Mondriaan Mental Health Hospital, Mondriaan Ouderenzorg, Kloosterkensweg 10, 6419 PJ, Heerlen-Maastricht, The Netherlands.
Background: Medication use is increasing in psychiatric populations, particularly those with personality disorders (PDs). Older adults with PDs are at higher risk for adverse drug reactions (ADRs), which may interfere with daily functioning.
Objectives: This study aimed to describe medication use and health-related quality of life (HR-QOL) in older adults with PDs compared with control groups and to evaluate predictors of medication use and HR-QOL.
Eur J Pain
October 2025
School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Background: Pain is a significant burden on individuals, healthcare systems and society. Analgesic drugs carry many therapeutic benefits; however, all drugs are associated with adverse effects and risk of harm. Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids have been identified as particularly high-risk due to the risk of side effects and/or dependency.
View Article and Find Full Text PDF